Evidence map›Paper›PMID 36794325›Full record

ArticleInternational journal of radiation biology2023

IPW-5371 mitigates the delayed effects of acute radiation exposure in WAG/RijCmcr rats when started 15 days after PBI with bone marrow sparing.

Brian L Fish, Barry Hart, Tracy Gasperetti, Jayashree Narayanan, Feng Gao, Dana Veley, Lauren Pierce, Heather A Himburg, Thomas MacVittie, Meetha Medhora

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Brian L FishDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Barry HartInnovation Pathways, Palo Alto, CA, USA.
Tracy GasperettiDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Jayashree NarayananDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Feng GaoDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Dana VeleyDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Lauren PierceDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Heather A HimburgDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Thomas MacVittieInnovation Pathways, Palo Alto, CA, USA.
Meetha MedhoraDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USInnovation Pathways · US

Funding

Development of lisinopril for post-exposure mitigation of late effects from a radU01AI107305 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI MEDHORA, MEETHA M · 2013 to 2017
$3.0M
Mechanism of radiation induced endovascular injury and mitigation via the Notch-Dll4 pathwayU01AI133594 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI HIMBURG, HEATHER A · 2018 to 2022
$3.0M
NIAID NIH HHS HHSN272201800012CNIAID NIH HHS U01 AI107305NIAID NIH HHS U01 AI133594
6 · The paper itself

Abstract

purposeTo test IPW-5371 for the mitigation of the delayed effects of acute radiation exposure (DEARE). Survivors of acute radiation exposure are at risk for developing delayed multi-organ toxicities; however, there are no FDA-approved medical countermeasures (MCM) to mitigate DEARE.

methodsWAG/RijCmcr female rat model of partial-body irradiation (PBI), by shielding part of one hind leg, was used to test IPW-5371 (7 and 20 mg kg

resultsIPW-5371 enhanced survival (primary endpoint) as well as attenuated secondary endpoints of lung and kidney injuries by radiation.

conclusionTo provide a window for dosimetry and triage, as well as avoid oral delivery during the acute radiation syndrome (ARS), the drug regimen was started at 15 d after 13.5 Gy PBI. The experimental design to test mitigation of DEARE was customized for translation in humans, using an animal model of radiation that was designed to simulate a radiologic attack or accident. The results support advanced development of IPW-5371 to mitigate lethal lung and kidney injuries after irradiation of multiple organs.

Indexed as

Acute Radiation SyndromeRadiation Injuries, ExperimentalAnimalsBone MarrowFemaleHumansLungRadiation DosageRatsDEAREMitigationpartial body irradiationradiation nephropathyradiation pneumonitis

Identifiers

PMID36794325
PMCPMC10330589
OpenAlexW4321003960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.